Current and Potential Applications of Bismuth-Based Drugs

Keogan, Donal M; Griffith, Darren M.

doi:10.3390/molecules190915258

Cited by 166 publications

(102 citation statements)

References 130 publications

(259 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1,2] In particular platinum (Pt) drugs such as cisplatin, carboplatin and oxaliplatin, Figure 1, have played a very important and well documented role in treating cancer and are employed in nearly 50% of anti-cancer regimens. [3] …”

Section: Introductionmentioning

confidence: 99%

Development of a novel carboplatin like cytoplasmic trackable near infrared fluorophore conjugate via strain-promoted azide alkyne cycloaddition

Kitteringham

Cheung

et al. 2018

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Development of a novel carboplatin like cytoplasmic trackable near infrared fluorophore conjugate via strain-promoted azide alkyne cycloaddition

Kitteringham

Cheung

et al. 2018

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

“…Furthermore, it possess antibacterial effects by inhibiting various enzymes produced by H. py Data are presented as n (%) with 95% CI. See Table 1 lori (including urease, catalase, and lipase/phospholipase), preventing adhesion of H. pylori to surface epithelial cells, and inhibiting ATP synthesis and some membrane functions in H. pylori [20][21][22]. It has been reported that the addition of bismuth to standard triple therapy improved the eradication rate [23,24].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen

et al. 2017

View full text Add to dashboard Cite

i.d, levofloxacin 500 mg, once daily). The primary outcome was the eradication rate in the intention-to-treat (ITT) and per protocol (PP) analysis. Results: The eradication rates of the above 3 groups using ITT analysis were RBAL 83.8%, RBMT 88.3%, and RAL 74.8% compared with 91.2, 92.5, and 79.2%, respectively, using PP analysis. The eradication rate using RBMT was significantly higher than that of RAL (p = 0.029 in ITT analysis and p = 0.017 in PP analysis). Several side effects occurred in 156 patients (54.1%) KeywordsHelicobacter pylori infection · Bismuth-containing quadruple therapy · Levofloxacin-containing triple therapy · Eradication rate Abstract Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a firstline regimen for the eradication of Helicobacter pylori. Methods: A total of 329 patients with H. pylori infection were randomly divided into 3 groups to receive one of the following regimens: (a) levofloxacin-containing bismuth quadruple Significance of the Study• This study compared the efficacy of 3 Helicobacter pylori eradication regimens, 2 of which contained levofloxacin, as the first line of treatment. Both quadruple regimens (standard bismuth quadruple therapy or levofloxacin-containing bismuth quadruple therapy) were highly effective in eradicating the infection and significantly superior to levofloxacin-containing triple therapy. Quadruple therapies should be used as first-line therapy for H. pylori infection.

show abstract

“…Bismuth (Z=83) has been used for over 100 years as an over-the-counter remedy for gastrointestinal problems[144]. Bismuth has the highest K-edge energy (91 keV) of all the elements under consideration and as a result, it shows less change in CT number across different kVp settings compared to iodine and barium.…”

Section: Choice Of Elements For Spectral Ct Contrast Materialsmentioning

confidence: 99%

Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies

Yeh

Fitzgerald

Edic

et al. 2017

Advanced Drug Delivery Reviews

165

144

View full text Add to dashboard Cite

The introduction of spectral CT imaging in the form of fast clinical dual-energy CT enabled contrast material to be differentiated from other radiodense materials, improved lesion detection in contrast-enhanced scans, and changed the way that existing iodine and barium contrast materials are used in clinical practice. More profoundly, spectral CT can differentiate between individual contrast materials that have different reporter elements such that high-resolution CT imaging of multiple contrast agents can be obtained in a single pass of the CT scanner. These spectral CT capabilities would be even more impactful with the development of contrast materials designed to complement the existing clinical iodine- and barium-based agents. New biocompatible high-atomic number contrast materials with different biodistribution and X-ray attenuation properties than existing agents will expand the diagnostic power of spectral CT imaging without penalties in radiation dose or scan time.

show abstract

Current and Potential Applications of Bismuth-Based Drugs

Cited by 166 publications

References 130 publications

Development of a novel carboplatin like cytoplasmic trackable near infrared fluorophore conjugate via strain-promoted azide alkyne cycloaddition

Development of a novel carboplatin like cytoplasmic trackable near infrared fluorophore conjugate via strain-promoted azide alkyne cycloaddition

Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen

Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies

Contact Info

Product

Resources

About